secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allarity Therapeutics, Inc. (ALLR)
CIK:        0001860657
Form:       8-K
Filed at:   2025-07-07T23:59:59+00:00
Accession:  0001213900-25-061639
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allarity Therapeutics CFO resigns; appoints Jeffrey Ervin as part-time CFO effective July 1, 2025
--------------------------------------------------------------------------------

- CFO Alexander Epshinsky resigned June 30, 2025; not due to any disagreement with the company.
- Jeffrey S. Ervin appointed part-time CFO on July 1, 2025; annual base salary of $175,000.
- Ervin previously served as fractional co-CFO of DDC Enterprise (NYSE: DDC) and chairman/CEO of IMAC Holdings (Nasdaq: BACK).
- Ervin also serves as independent director of Cingulate, Inc. (Nasdaq: CING); holds MBA from Vanderbilt.
- Severance: 6 months' base salary if terminated after Change-of-Control, subject to signed release.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860657/000121390025061639/0001213900-25-061639-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860657/000121390025061639/ea0248238-8k_allarity.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-061639

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer